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Comment on: Clinical cure rates in subjects treated with azithromycin for community-acquired 29 
respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant 30 
Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. 31 
Zhanel et al. report that Streptococcus pneumoniae azithromycin MICs ш ?ŵŐ ?> ?compared to 32 
<0.5mg/L, predict worse outcomes in azithromycin treated S. pneumoniae respiratory tract 33 
infections.
1
 This relationship between MIC and outcome is not a linear dose (MIC) response 34 
ƌĞůĂƚŝŽŶƐŚŝƉ ?tŚŝůƐƚĂŶD/ш ?ŵŐ ?>ƉƌĞĚŝĐƚƐǁŽƌƐĞŽƵƚĐŽŵĞƐ ?outcomes are no different if the S. 35 
pneumoniae MIC is 2-8mg/L ?ш ? ?Žƌш 64mg/L. The absence of a linear dose (MIC) response 36 
relationship is not explained and raises the possibility that the MIC is not causally related to 37 
outcomes.
2 
Defining if an MIC is causally related to outcome is important to ensure the maximal 38 
benefit from azithromycin treatment can be obtained. Given this non-linear dose response 39 
relationship I suggest further analysis is required to understand the study findings. Specifically, an 40 
analysis of individual patient factors should be completed. It may be that patient factors e.g. age, co-41 
morbidities, previous episodes of respiratory tract infection or macrolide treatment, are associated 42 
with both treatment failure and azithromycin MICs. A study by Moreno et al. supports this possible 43 
explanation, they showed nosocomial acquisition of a S. pneumoniae infection was a risk factor for 44 
macrolide (erythromycin) resistance.
3
 Data from Holmes et al. has also shown that raised MICs are 45 
not always causally related to outcomes. Holmes et al. investigated outcomes from Staphylococcus 46 
aureus bacteraemia in relation to vancomycin MICs.
4
 A multivariate analysis determined that raised 47 
vancomycin MICs were associated with poorer clinical outcomes, even in the absence of vancomycin 48 
treatment. Might a raised S. pneumoniae azithromycin MIC also be a predictor of a poorer outcome, 49 
but not one related to a reduced efficacy of azithromycin treatment? A multivariate analysis is 50 
required to determine if patient factors may explain the observed association between azithromycin 51 
resistance and outcome in the treatment of S. pneumoniae respiratory tract infection. Such analyses 52 
have been completed for penicillin treated S. pneumoniae respiratory tract infections. One such 53 
analysis by Pallares et al. showed that after adjusting for co-morbidities the odds ratio for mortality 54 
in patients with penicillin-resistant, compared to penicillin sensitive strains, was 1.0.
5
 If patient 55 
factors do explain the association between MICs of ш ?ŵŐ ?>ĂŶĚĐůŝŶŝĐal failure, MIC criteria defining 56 
resistance for azithromycin treatment of S. pneumoniae respiratory tract infections may be 57 
unhelpful in predicting an individuals risk of treatment failure.    58 
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